Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. ADG 116 administered intravenously (IV) over a period of 60-90 minutes. The study planned to treated 42 patients.
Solid Tumor
DRUG: ADG116
Number of participants experiencing dose-limiting toxicities, From first dose of ADG116 (Week 1 Day 1) until 30days after the last ADG116 injection (up to 2 years)|Number of participants experiencing clinical and laboratory adverse events (AEs), From first dose of ADG116 (Week 1 Day 1) until 30days after the last ADG116 injection (up to 2 years)
This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. ADG 116 administered intravenously (IV) over a period of 60-90 minutes. The study planned to treated 42 patients.